cornell medical college

Weill Cornell Medical College receives 2 $100,000 grants for inn...

EurekAlert! - Chemistry, Physics and Materials Sciences  Wed, 10/29/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) Weill Cornell Medical College announced today that it has received two $100,000 Grand Challenges Explorations grants from the Bill & Melinda Gates Foundation.

The grants will support innovative global health research projects: "Untimely Triggering of the Fusion Mechanism Used by Viruses for Entry: A New Antiviral Approach Using Engineered Microparticles," conducted by Dr.

Anne Moscona, and "Senescent and Rejuvenated Mtb Subsets on Exit from Latency," conducted by Dr. Carl Nathan.


 

Nanotechnology: The big future of tiny medicine

EurekAlert! - Chemistry, Physics and Materials Sciences  Mon, 09/22/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) The symposium will examine the use of nano-and micro-fabrication tools and explore techniques for clinical and basic life sciences research, including the development of drug delivery systems, biosensors and fluidic devices, implantable devices, and tissue scaffolds with applications in medical diagnostics and imaging, treatment of cancer and other degenerative diseases, and in orthopedics and wound repair.


 

Potential new drug target to fight tuberculosis identified

EurekAlert! - Chemistry, Physics and Materials Sciences  Tue, 07/29/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) With antibiotic resistance on the rise, tuberculosis is emerging as a bigger global health threat than ever before.

But now, innovative research at Weill Cornell Medical College suggests that Mycobacterium tuberculosis has an as yet unsuspected weakness -- one that could be a prime target for drug development.


 

Results of 9-month phase II study of gammagard intravenous immun...

EurekAlert! - Chemistry, Physics and Materials Sciences  Tue, 07/29/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) NewYork-Presbyterian Hospital/Weill Cornell Medical Center announced today the nine-month interim results of an ongoing Phase II clinical trial of GAMMAGARD Intravenous Immunoglobulin for Alzheimer's disease at the Alzheimer's Association International Conference on Alzheimer's Disease in Chicago.


 

N.Y. research team discovers how antidepressants and cocaine int...

EurekAlert! - Chemistry, Physics and Materials Sciences  Mon, 07/28/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) In a first, scientists from Weill Cornell Medical College and Columbia University Medical Center have described the specifics of how brain cells process antidepressant drugs, cocaine and amphetamines.

These novel findings could prove useful in the development of more targeted medication therapies for a host of psychiatric diseases, most notably in the area of addiction.


 

Estrogen Helps Drive Distinct, Aggressive Form Of Prostate Cance...

ScienceDaily  Wed, 05/28/2008 - 20:45

Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.


 

Weill Cornell team identifies new cancer stem cell driving metas...

EurekAlert! - Chemistry, Physics and Materials Sciences  Mon, 05/26/2008 - 23:00

(New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College) The molecular profile of cancer stem cells that initiate metastatic colon tumors is significantly different from those responsible for primary tumors, according to new research from a team at Weill Cornell Medical College.